When evaluating biotech companies, the demand for their product is often clear, but the challenge lies in their ability to deliver on that promise.

In biotech or hard tech businesses, your primary metric might not be revenue or active users, especially if you're still validating whether your technology works. Instead, focus on technical milestones that demonstrate progress.

The focus for biotech companies is on de-risking their technology by obtaining experimental data and developing a viable therapeutic intervention, which is crucial before entering clinical trials.

Recent approvals of gene therapies and cell-based therapies have opened new avenues for biotech companies to create marketable products.

Biotech fundraising is increasingly resembling traditional paths seen in software, with many funds showing interest in innovative science companies.

For medical devices, the MVP should be successfully peer-reviewed science that supports your work and outlines a clear path to regulatory clearance.

The future of biotech will likely involve products that patients are willing to pay for, focusing on conditions that significantly impact their quality of life.

Biotech founders often make the mistake of not conducting the essential experiments needed to validate their ideas, fearing that failure could jeopardize their startups.

The biotech industry is experiencing a surge in startups due to unprecedented access to capital and advancements in therapeutic modalities.